Patent
Fast acting inhibitor of gastric acid secretion
| العنوان: | Fast acting inhibitor of gastric acid secretion |
|---|---|
| Patent Number: | 11510,894 |
| تاريخ النشر: | November 29, 2022 |
| Appl. No: | 12/086379 |
| Application Filed: | January 25, 2007 |
| مستخلص: | The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion. |
| Inventors: | Geibel, John P. (Branford, CT, US); Kirchhoff, Philipp (Attendorn, DE) |
| Claim: | 1. A pharmaceutical composition adapted for oral administration to gastric juices in the stomach of a human patient in need of a rapid increase in gastric pH consisting essentially of an effective amount of a proton pump inhibitor and at least one pharmaceutically acceptable zinc salt selected from the group consisting of zinc acetate, zinc chloride, zinc gluconate, zinc lactate, zinc picolinate, zinc tartrate and mixtures thereof formulated for direct delivery of said zinc salt and said proton pump inhibitor to and dissolution in the gastric juices from said composition to rapidly increase the pH of the gastric juices in the stomach of said patient in need thereof to at least 3.0 within a period no greater than one hour after oral administration, wherein said composition further includes a pharmaceutically acceptable carrier, additive or excipient, and said composition excludes a buffering agent and additional compounds that increases the gastric pH. |
| Claim: | 2. The composition according to claim 1 wherein said amount of zinc salt in said composition is effective to raise the pH of the gastric juices in the stomach of said patient to at least 3.5 within a period no greater than 30 minutes after administration. |
| Claim: | 3. The composition according to claim 1 wherein said amount of zinc salt is effective to raise the pH of the gastric juices in the stomach of said patient to at least 4.0. |
| Claim: | 4. The composition according to claim 1 wherein said zinc salt is zinc acetate. |
| Claim: | 5. The composition according to claim 1 wherein said zinc salt is zinc chloride. |
| Claim: | 6. The composition according to claim 1 wherein said zinc salt is zinc gluconate. |
| Claim: | 7. The composition according to claim 1 wherein said zinc salt is zinc lactate. |
| Claim: | 8. The composition according to claim 1 wherein said zinc salt is zinc picolinate. |
| Claim: | 9. The composition according to claim 1 wherein said zinc salt is zinc tartrate. |
| Claim: | 10. The composition according to claim 1 wherein said zinc salt is a mixture of said zinc salts. |
| Claim: | 11. The composition according to claim 10 wherein said mixture of zinc salts includes zinc acetate. |
| Claim: | 12. The composition according to claim 10 wherein said mixture of zinc salts includes zinc chloride. |
| Claim: | 13. The composition according to claim 10 wherein said mixture of zinc salts includes zinc gluconate. |
| Claim: | 14. The composition according to claim 10 wherein said mixture of zinc salts includes zinc lactate. |
| Claim: | 15. The composition according to claim 10 wherein said mixture of zinc salts includes zinc picolinate. |
| Claim: | 16. The composition according to claims 1 wherein said proton pump inhibitor is esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole or mixtures thereof. |
| Claim: | 17. The composition according to claims 2 wherein said proton pump inhibitor is esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole or a mixture thereof. |
| Claim: | 18. The composition according to claims 3 wherein said proton pump inhibitor is esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole or a mixture thereof. |
| Claim: | 19. The composition according to claim 1 wherein said proton pump inhibitor is esomeprazole. |
| Claim: | 20. The composition according to claim 2 wherein said proton pump inhibitor is esomeprazole. |
| Claim: | 21. The composition according to claim 3 wherein said proton pump inhibitor is esomeprazole. |
| Claim: | 22. The composition according to claim 1 wherein said proton pump inhibitor is omeprazole. |
| Claim: | 23. The composition according to claim 2 wherein said proton pump inhibitor is omeprazole. |
| Claim: | 24. The composition according to claim 3 wherein said proton pump inhibitor is omeprazole. |
| Claim: | 25. The composition according to claim 3 wherein said proton pump inhibitor is lansoprazole. |
| Claim: | 26. The composition according to claim 3 wherein said proton pump inhibitor is pantoprazole. |
| Claim: | 27. The composition according to claim 3 wherein said proton pump inhibitor is rabeprazole. |
| Claim: | 28. The composition according to claim 3 wherein said proton pump inhibitor is a mixture of at least two compounds selected from the group consisting of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole. |
| Claim: | 29. The composition according to claim 10 wherein said mixture of zinc salts includes zinc tartrate. |
| Claim: | 30. The composition according to claim 2 wherein said zinc salt is at least one zinc salt selected from the group consisting of zinc acetate, zinc chloride and zinc gluconate and optionally at least one zinc salt selected from the group consisting of zinc lactate, zinc picolinate and zinc tartrate. |
| Claim: | 31. The composition according to claim 3 wherein said zinc salt is at least one zinc salt selected from the group consisting of zinc lactate, zinc picolinate and zinc tartrate and optionally at least one zinc salt selected from the group consisting of zinc gluconate, zinc acetate and zinc chloride. |
| Claim: | 32. The composition according to claim 13 wherein said proton pump inhibitor is esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole or a mixture thereof. |
| Claim: | 33. The composition according to claim 14 wherein said proton pump inhibitor is esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole or a mixture thereof. |
| Claim: | 34. The composition according to claim 15 wherein said proton pump inhibitor is esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole or a mixture thereof. |
| Claim: | 35. The composition according to claim 32 wherein said proton pump inhibitor is omeprazole. |
| Claim: | 36. The composition according to claim 33 wherein said proton pump inhibitor is omeprazole. |
| Claim: | 37. The composition according to claim 34 wherein said proton pump inhibitor is omeprazole. |
| Patent References Cited: | 4292324 September 1981 Jonsson et al. 6166071 December 2000 Ashmead et al. 6596708 July 2003 Petrus 6613354 September 2003 Depui et al. 6930099 August 2005 Petrus 8512761 August 2013 Geibel et al. 2002/0064555 May 2002 Cullen 2002/0198165 December 2002 Bratzler et al. 2003/0068326 April 2003 Gevas et al. 2003/0077333 April 2003 Phillips et al. 2004/0019102 January 2004 Kennedy 2004/0058014 March 2004 Steegers-Theunissen et al. 2004/0126333 July 2004 Galli et al. 2004/0180850 September 2004 Natunen et al. 2004/0248942 December 2004 Hepburn et al. 2005/0147675 July 2005 Petrus 2005/0238731 October 2005 Holt 2005/0244517 November 2005 Hall 2006/0235053 October 2006 Gebauer et al. 2006/0251722 November 2006 Bandak et al. 2008/0014288 January 2008 Huval et al. 2008/0038370 February 2008 Holt 2009/0035393 February 2009 Geibel et al. 2010/0015086 June 2010 Geibel et al. 0303380 February 1989 0942720 August 2003 WO95/25513 September 1995 WO-9631213 October 1996 9810773 March 1998 WO 9816218 April 1998 WO03/066001 August 2003 2004099182 November 2004 WO2004/099182 November 2004 WO2005/011692 February 2005 WO2005/076987 August 2005 WO 2006/073779 July 2006 2007089511 August 2007 WO2009/017624 February 2009 |
| Other References: | Jeejeebhoy, Canadian Medical Association Journal, 166: 1297-1302 (2002). cited by examiner Baskan et al., Biotechnology & Biotechnological Equipment, 20: 146-150 (2006). cited by examiner PubMed Health Glossary, “Upper Gastrointestinal Tract”, accessed at https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0022854/, on Nov. 14, 2016. cited by examiner Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Rapp BA, Wheeler DL Nucl. Acids Res. 28:15-18 (2000). cited by applicant Cho CH, Ogle CW and Dai S, Effects of Zinc Sulphate Pretreatment on Gastric Acid Secretion and Lesion Formation in Rats infused Intravenously with Graded Doses of Methacholine. Pharmacology 17:32-38 (1978). cited by applicant Green OP, Deoraj P, Gopoinath C, Crook D, Matsuda K. Toxxicity of the novel antipeptic ulcer agent catena-(S)-[mu-(3-aminopropionyl)histidinato (2-)-N1,N2, Q:N tau]-zinc in male cynomolgus monkets. Arzneimittelforschung. May 1993; 43:562-9. cited by applicant Kuwayama J, Takahashi M, Suzuki K, Suga M, Takata H, Ohara T, Koizumi K, Kiriyama Y. Polaprezinc. Nippon Rinsho. Feb. 2002; 60 Suppl 2:717-20. Review. Japanese. No Abstract Available. cited by applicant Matsuda K, Yamaguchi I, Wada H.,Toxicity of the novel anti-peptic ulcer agent polaprrezinc in beagle dogs. Arzneimittelforschung. Jan. 1995; 45:52-60. cited by applicant Otaka M. Chaperon-induction therapy for peptic ulcers. Nippon Rinsho. Feb. 2002; 60 Suppl 2:572-6. Review. Japanese. No abstract available. cited by applicant Nishiwaki H, Kato S. Takeuchi K. Irritant action of monochloramine in rat stomachs: effects of zinc L-carnosine (polaprezinc)Gen Pharmacol. Nov. 1997; 29: 713-8. cited by applicant Varas Lorenzo MJ, Lopez Martinez A; Gordillo Bernal J; Mundet Surroca J; Hospital Creu Roja, L'Hospitalet de Llobregat Revista Espanola de enfermedades digestivas: organo official de la Sociedad Espanola de Patologia Digestiva (1991) 80: 91-4 [ISSN 1130-0108]. cited by applicant Yoshikawa T, Naito Y, Tanigawa T, Yoneta T, Kondo M. The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-L-histidinato zinc. Biochim Biophys Acta Nov. 14, 1991; 1115:15-22. cited by applicant Functional Ingredients Staff, Zinc Carnosine A New Peptic Ulcer Treatment. Functional Ingredients Nov. 2002, 2pp. cited by applicant U.S. Appl. No. 11/881,176, filed Jul. 21, 2007, Geibel et al. cited by applicant Aarimaa M, Soderstrom KO, Kalimo H, Inberg M, Nevalainen T. Morphology and function of the parietal cells after proximal selective vagotomy in duodenal ulcer 20 patients. Scand J Gastroenterol 1984;19:787-797. cited by applicant Abelo A, Eriksson UG, Karlsson MO, Larsson H, Gabrielsson J. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog. J Pharmacol Exp Ther 2000;295:662-669. cited by applicant Adachi K, Komazawa Y, Fujishiro H, Mihara T, Ono M, Yuki M, Kawamura A, Karim Rumi MA, Amano Y, Kinoshita Y. Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol 2003;38:830-835. cited by applicant Aihara T, Nakamura E, Arnagase K, Tomita K, Fujishita T, Furutani K, Okabe S. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future. Pharmacol Ther 2003;98:109-127. cited by applicant Alino SF, Garcia D, Uvnas-Moberg K. On the interaction between intragastric pH and electrical vagal stimulation in causing gastric acid secretion and intraluminal release of gastrin and somatostatin in anesthetized rats. Acta Physiol Scand 1983;117:491-495. cited by applicant Amdrup E. The surgical treatment of duodenal ulcer. Schweiz Med Wochenschr 1979;109:583-585. cited by applicant Andersen JB, Andrade DV, Wang T. Effects of inhibition gastric acid secretion on arterial acid-base status during digestion in the toad Bufo marinus. Comp Biochem Physiol A Mol Integr Physiol 2003;135:425-433. cited by applicant Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294-307. cited by applicant Babenko GA and Parashchak AP. [Iron, copper, cobalt and zinc contents of gastric juice of dogs with experimental stomach ulcer]. Patol Fiziol Eksp Ter 12: 65-67, 1968. cited by applicant Bell NJ, Hunt RH. Progress with proton pump inhibition. Yale J Biol Med 1992;65:649-657. cited by applicant Blachar A, Federle MP. Gastrointestinal complications of laparoscopic roux-en-Y gastric bypass surgery in patients who are morbidly obese: findings on radiography and CT. AJR Am J Roentgenol 2002;179:1437-1442. cited by applicant Brzozowski T, Konturek PC, Konturek SJ, Drozdowicz D, Kwiecien S, Pajdo R, Bielanski W, Hahn EG. Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers. Eur J Pharmacol 2000;398:147-158. cited by applicant Busque SM, Kerstetter JE, Geibel JP, Insogna K. L-type amino acids stimulate gastric acid secretion by activation of the calcium-sensing receptor in parietal cells. Am J Physiol Gastrointest Liver Physiol 2005;289:G664-G669. cited by applicant Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997;11:473-482. cited by applicant Cho CH, Fong LY, Ma PC, Ogle CW. Zinc deficiency: its role in gastric secretion and stress-induced gastric ulceration in rats. Pharmacol Biochem Behav 1987;26:293-297. cited by applicant Cho CH, Fong LY, Wong SH, Ogle CW. Zinc deficiency worsens ethanol-induced gastric ulcers in rats. Drug Nutr Interact 1988;5:289-295. cited by applicant Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999;11:1277-1282. cited by applicant Diamond I, Hurley LS. Histopathology of zinc-deficient fetal rats. J Nutr 1970;100:325-329. cited by applicant Dufner MM, Kirchhoff P, Remy C, Hafiier P, Muller MK, Cheng SX, Tang LQ, Hebert SC, Geibel JP, Wagner CA. The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands. Am J Physiol Gastrointest Liver Physiol 2005;289:G1084-G1090. cited by applicant Elmes ME, Jones JG. Ultrastructural studies on Paneth cell apoptosis in zinc deficient rats. Cell Tissue Res 1980;208:57-63. cited by applicant Fong LY, Lee JS, Chan WC, Newberne PM. Zinc deficiency and the development of esophageal and forestomach tumors in Sprague-Dawley rats fed precursors of N-nitroso-N-benzyl.methylamine. J Natl Cancer Inst 1984;72:419-425. cited by applicant Forte JG, Ly B, Rong Q, Ogihara S, Ramilo M, Agnew B, Yao X. State of actin in gastric parietal cells. Am J Physiol 1998;274:C97-104. cited by applicant Franzin G, Manfrini C, Musola R, Rodella S, Fratton A. Chronic erosions of the stomach—a clinical, endoscopic and histological evaluation. Endoscopy 1984;16:1-5. cited by applicant Frommer DJ. The healing of gastric ulcers by zinc sulphate. Med J Aug. 1975;2:793-796. cited by applicant Gardner JD, Sloan S, Miner PB, Robinson M. Meal-stimulated gastric acid secretion and integrated gastric acidity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17:945-953. cited by applicant Garnett WR. Lansoprazole: a proton pump inhibitor. Ann Pharmacother 1996;30:1425-1436. cited by applicant Gedda K, Scott D, Besancon M, Lorentzon P, Sachs G. Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995;109:1134-1141. cited by applicant Geibel JP, Wagner CA, Caroppo R, Qureshi I, Gloeckner J, Manuelidis L, Kirchhoff P, Radebold K. The stomach divalent ion-sensing receptor scar is a modulator of gastric acid secretion. J Biol Chem 2001;276:39549-39552. cited by applicant Geibel JP. Secretion and absorption by colonic crypts. Annu Rev Physiol 2005;67:471-490. cited by applicant Geibel R. Role of potassium in acid secretion. World J Gastroenterol 2005;11:5259 5265. cited by applicant Helander HF, Keeling DJ. Cell biology of gastric acid secretion. Baillieres Clin Gastroenterol 1993,7:1-21. cited by applicant Hersey SJ, Sachs G. Gastric-Acid Secretion. Physiological Reviews 1995;75:155-189. cited by applicant Hirschowitz BI, Keeling D, Lewin M, Okabe S, Parsons M, Sewing K, Wallmark B, Sachs G. Pharmacological Aspects of Acid-Secretion. Digestive Diseases and Sciences 1995;40:S3-S23. cited by applicant Horie S, Yano S, Watanabe K. Effects of drugs acting on Cl(−)-. Eur JPharmacol 1992;229:15-19. cited by applicant Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG, Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells. Science 2004;306:1568-1571. cited by applicant Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or Iansoprazole. Aliment Pharmacol Ther 2000;14:709-714. cited by applicant Kirchhoff P, Wagner CA, Gaetzschmann F, Radebold K, Geibel R. Demonstration of a functional apical sodium hydrogen exchanger in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2003;285:G1242-G1248. cited by applicant Kirchhoff P, Andersson K, Socrates T, Sidani SM, Kosiek 0, Geibel JP. Characteristics of the K+-competitive H+,K+-ATPase Inhibitor AZD0865 in isolated rat gastric glands. Am J Physiol Gastrointest Liver Physiol 2006. cited by applicant Kirchhoff P, Dave MH, Remy C, Kosiek 0, Busque SM, Dufner M, Geibel JP, Verrey F, Wagner CA. An amino acid transporter involved in gastric acid secretion. Pflugers Arch 2006;451:738-748. cited by applicant Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR, III, De LG. Willingness to pay for complete symptom relief of gastroesophageal reflux disease.Arch Intern Med 2002;162.1361-1366. cited by applicant Knauf F, Yang CL, Thomson RB, Menton SA, Giebisch G, Aronson PS. Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells. Proc Natl Acad Sci U S A 2001;98:9425-9430. cited by applicant Lehmann F, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs 2003;63:1785-1797. cited by applicant Locke GR, M. Current medical management of gastroesophageal reflux disease. Thorac Surg Clin 2005;15:369-375. cited by applicant Lorentzon P, Scott D, Hersey S, Wallmark B, Rabon E, Sachs G. The gastric H+,K+-ATPase. Prog Clin Biol Res 1988;273:247-254. cited by applicant McDaniel N, Lytle C. Parietal cells express high levels of Na—K—2C1 cotransporter on migrating into the gastric gland neck. Am J Physiol 1999;276:G1273-G1278. cited by applicant Meulemans AL, Eelen JG, Schuurkes JA. NO mediates gastric relaxation after brief vagal stimulation in anesthetized dogs. Am J Physiol 1995;269:G255-G261. cited by applicant Naess K. [Zinc in the treatment of stomach ulcer]. Tidsskr Nor Laegeforen 1976;96:1334. cited by applicant Ng WL, Fong LY, Ma L, Newberne PM. Dietary zinc deficiency and tumorigenesis: a scanning electron microscope study. J Electron Microsc (Tokyo) 1984;33:344-348. cited by applicant Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-767. cited by applicant Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-1339. cited by applicant Peulen O, Denis G, Defresne MP and Dandrifosse G. Spermine-Induced alteration of small intestine in suckling rat: involvement of apoptosis or Zn2+ enzymes? Dig Dis Sci 46: 2490-2498, 2001. cited by applicant Prinz C, Kajimura M, Scott D, Helander H, Shin J, Besancon M, Bamberg K, Hersey S, Sachs G. Acid secretion and the H,K ATPase of stomach. Yale J Biol Med 1992;65:577-596. cited by applicant Raugstad TS, Svanes K, Ulven A, Moister A. Interaction between acute gastric ulcer and epinephrine-induced mucosal erosions in the rat: the significance of gastric acid secretion. Digestion 1979;19:70-72. cited by applicant Robinson M. Drugs, bugs, and esophageal pH profiles. Yale J Biol Med 1999;72:169-172. cited by applicant Sachs G, Scott D, Reuben M. Omeprazole and the gastric mucosa. Digestion 1990;47 Suppl 1:35-38. cited by applicant Sachs G, Shin JM, Pratha V, Hogan D. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors. Today (Barc) 2003;39 Suppl A:11-14. Drugs. cited by applicant Sachs G. Physiology of the parietal cell and therapeutic implications. Pharmacotherapy 2003;23:68S-73S. cited by applicant Sachs G, Walimark B. The gastric H+,K+-ATPase: the site of action of omeprazole. 10 Scand J Gastroenterol Suppl 1989;166:3-11. cited by applicant Sachs G. The parietal cell as a therapeutic target. Scand J Gastroenterol Suppl 1986;118:1-10. cited by applicant Sachs G, Prinz C, Loo D, Bamberg K, Besancon M, Shin JM. Gastric acid secretion: activation and inhibition. Yale J Biol Med 1994;67:81-95. cited by applicant Sanders SW, Moore JG, Day GM, Tolman KG. Circadian differences in pharmacological blockade of meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1992;6:187-193. cited by applicant Schultheis PJ, Clarke LL, Meneton P, Harlin M, Boivin GP, Stemmermann G, Duffy JJ, Doetschman T, Miller ML, Shull GE. Targeted disruption of the murine Na+/H+ exchanger isoform 2 gene causes reduced viability of gastric parietal cells and loss of net acid secretion. J Clin Invest 1998;101:1243-1253. cited by applicant Scott DR, Helander HF, Hersey SJ, Sachs G. The site of acid secretion in the mammalian parietal cell. Biochim Biophys Acta 1993;1146:73-80. cited by applicant Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Baillieres Clin Gastroenterol 1993;7:23-54. cited by applicant Singh J. Prostaglandin release from rat stomach following vagal stimulation or administration of acetylcholine. Eur J Pharmacol 1980;65:39-48. cited by applicant Soumarmon A, Lewin MJ. Gastric (H+,K+)-ATPase. Biochimie 1986;68:1287-1291. cited by applicant Sunderman FW, Jr. The influence of zinc on apoptosis. Ann Clin Lab Sci 1995;25:134-142. cited by applicant Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004;16:441-443. cited by applicant Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001;13 Suppl 1:S29-S33. cited by applicant Urushidani T, Forte JG. Signal transduction and activation of acid secretion in the parietal cell. J Membr Biol 1997;159:99-111. cited by applicant Waisbren SJ, Geibel J, Boron WF, Modlin IM. Luminal perfusion of isolated gastric glands. Am J Physiol 1994;266:01013-C1027. cited by applicant Waisbren SJ, Geibel JP, Modlin IM, Boron WF. Unusual permeability properties of gastric gland cells. Nature 1994;368:332-335. cited by applicant Waisbren SJ, Modlin IM. The evolution of therapeutic vagotomy. Surg Gynecol Obstet 1990;170:261-272. cited by applicant Wallmark B, Lorentzon P, Sachs G. The gastric H+,K(+)-ATPase. J Intern Med Suppl 1990;732:3-8. cited by applicant Watanabe T, Arakawa T, Fukuda T, Higuchi K, Kobayashi K. Zinc deficiency delays gastric ulcer healing in rats. Dig Dis Sci 1995;40:1340-1344. cited by applicant Williams JL. Gastroesophageal reflux disease: clinical manifestations. Gastroenterol Nurs 2003;26:195-200. cited by applicant Wolfe MM, Welage LS, Sachs G. Proton pump inhibitors and gastric acid secretion. Am J Gastroenterol 2001;96:3467-3468. cited by applicant Conchillo, A et al., Cytoprotective and antisecretory activity of a ranitidine-zinc complex. Prostaglandins Leukot Essent Fatty Acids. Jun. 1995;52(6);393-7. cited by applicant Ozutemiz, A O, et al., Effect of omeprazole on plasma zinc levels after oral zinc administration. Indian Journal of Gastroenterology 2002;21:216-218. cited by applicant Serfaty-Lacrosniere, C., et al., Hypochlorhydria from Short-Term Omeprazole Treatment Does Not Inhibit Intestinal Absorption of Calcium, Phosphorus, Magnesium or Zinc from Food in Humans. Journal of the American College of Nutrition. 1995;14:364-368. cited by applicant Reed, J C, et al., Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408-418. cited by applicant Rainsford, K D, et al., Anti-ulcer Activity of a Slow-release Zinc Complex, Zinc Monoglycerolate (Glyzinc). J. Pharm. Pharmacol. Jun. 1992;44(6):476-482. cited by applicant Bandyopadhyay, B , et al., Protective effect of zinc gluconate on chemically induced gastric ulcer. Indian J. Med. Res. Jul. 1997;106:27-32. cited by applicant Nascimento, JW et al., “Anti-Inflammatory Activity and Gastric Lesions Induced by Zinc-Tenoxicam” Pharmacology 2003; 68:64-69. cited by applicant Suzuki, K et al., “Prostaglandin E Inhibits Indomethacin-Induced Gastric Lesions through EP-1 Receptors” Digestion 2001;63:92-101. cited by applicant Clinical Research on Zinc Acexamate for the Treatment of Helicobacter Pylori-related Gastric Ulcers. Anthology of Medicine (Dec. 2000), 19(6), 870-871. (Chinese language article and its English language translation). cited by applicant Wang Shenghao, Zhang Xinyue, Zheng Gaoli, Lin Fang, Chen Jue. Study on the Action of Norfloxacin Zinc Against Experimental Gastric Ulcer in Rats; China Pharmacy (Nov. 2001), 12(11), 650-652. (Chinese language article and its English language translation). cited by applicant Cho, C. H. et al., The effects of Zinc Sulphate on Vagal-Induced Mast Cell Changes and Ulcers in the Rat Stomach; European Journal of Pharmacology 1977; 43:315-322. cited by applicant McLeay, I . . . M. et al.; Effects of intraruminal administration of zinc on gastric acid secretion in sheep; Research in Veterinary Science 1977; 23:243-245. cited by applicant Puscas I et al.; Effect of ZnSO4 upon gastric acid secretion and carbonic anhydrase. International Journal of Clinical Pharmacology, Therapy and Toxicology Jan. 1, 1985; vol. 23, pp. 609-612. ISSN: 0174-4879. cited by applicant Yamaguchi et al. Effect of Zinc on the Acidity of Gastric Secretion in Rats, Jul. 1980, Toxicology and Applied Pharmacology, 54:526-530. cited by applicant Arakawa et al. Effects of Zinc L-Carnosine on Gastric Mucosal and Cell Damage Caused by Ethanol in Rates, May 1990, Digestive Diseases and Sciences, 35(5): 559-566. cited by applicant Gardner JD et al.; Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration; 2002; J. Appl. Physiol. 92: 427-434. cited by applicant Ghosh T et al.: Review article: methods of measuring gastric acid secretion; 2011; Alimentary Pharmacology and Therapeutics 33:768-781. cited by applicant Kirchhoff P et al.; Zinc Salts Provide a Novel, Prolonged and Rapid Inhibition of Gastric Acid Secretion; 2011; Am J Gastroenterol 106:62-70. cited by applicant Robinson M et al.: Proton Pump Inhibitor Attitudes and Usage: A Patient Survey; Apr. 2002; P & T 27(4): 202-206. cited by applicant Testerman, TL et al.; Nutritional Requirements and Antibiotic Resistance Patterns of Helicobacter Species in Chemically Defined Media; May 2006; Journal of Clinical Microbiology 44(5): 1650-1658. cited by applicant Engels LGJ, et al. Iron, zinc, and copper balance in short bowel patients on oral nutrition. The American Journal of Clinical Nutrition, 1984;40:1038-1041. cited by applicant Farrell CP, et al. Proton Pump Inhibitors Interfere With Zinc Absorption and Zinc Body Stores. Gastroenterology Research, 2011;4(6):243-251. cited by applicant Demling L, Domschke W, Domschke S, Belohlavek D, Baenkler HW, Fruhmorgen P, Lingenberg G, Wunsch E, and Jaeger E. Treatment of duodenal ulcer with a long-acting synthetic secretin: a pilot trial. Acta Hepatogastroenterol (Stuttg) 22: 310-313, 1975. cited by applicant Flemstrom G and Turnberg LA. Gastroduodenal defence mechanisms. Clin Gastroenterol 13: 327-354, 1984. cited by applicant Fromm D. Gastric mucosal defense mechanisms: effects of salicylate and histamine. Am J Surg 135: 379-384, 1978. cited by applicant Glad H, Svendsen P, Olsen O, and Schaffalitzky de Muckadell OB. Importance of vagus nerves in duodenal acid neutralization in anesthetized pigs. Am J Physiol 272: G154-160, 1997. cited by applicant Halter F, Witzel L, Kohler B, and Hadorn B. Secretin snuff: evaluation of the action on pentagastrin-stimulated gastric acid secretion and on pancreatic bicarbonate production. Scand J Gastroenterol 10: 81-85, 1975. cited by applicant Helander HF and Keeling DJ. Cell biology of gastric acid secretion. Baillieres Clin Gastroenterol 7: 1-21, 1993. cited by applicant Hogan DL, Ainsworth MA, and Isenberg JI. Review article: gastroduodenal bicarbonate secretion. Aliment Pharmacol Ther 8: 475-488, 1994. cited by applicant Khropycheva RP, Zolotarev VA, and Polenov SA. [The role of histamine in vagal and gastrin effects on the secretory function of the rat stomach]. Ross Fiziol Zh Im I M Sechenova 86: 1539-1547, 2000. cited by applicant Kolkman JJ, Groeneveld AB, and Meuwissen SG. Effect of gastric feeding on intragastric P(CO2) tonometry in healthy volunteers. J Crit Care 14: 34-38, 1999. cited by applicant Lin TM, Evans DC, Shaar CJ, and Root MA. Action of somatostatin on stomach, pancreas, gastric mucosal blood flow, and hormones. Am J Physiol 244: G40-45, 1983. cited by applicant Malov Iu S and Kulikov AN. [Status of the bicarbonate-mucous barrier in patients with gastroduodenal pathology]. Ter Arkh 63: 34-37, 1991. cited by applicant Mertz HR and Walsh JH. Peptic ulcer pathophysiology. Med Clin North Am 75: 799-814, 1991. cited by applicant Quigley R and Baum M. Neonatal acid base balance and disturbances. Semin Perinatol 28: 97-102, 2004. cited by applicant Rees WD, Botham D, and Turnberg LA. A demonstration of bicarbonate production by the normal human stomach in vivo. Dig Dis Sci 27: 961-966, 1982. cited by applicant Soll AH. Peptic ulcer diseases. Perspectives on pathophysiology and therapy. J Clin Gastroenterol 11 Suppl 1: S1-5, 1989. cited by applicant Stevens MH, Thirlby RC, and Feldman M. Mechanism for high PCO2 in gastric juice: roles of bicarbonate secretion and CO2 diffusion. Am J Physiol 253: G527-530, 1987. cited by applicant Feldman M, Barnett CC. Gastric Bicarbonate Secretion in Patients with Duodenal Ulcer. Gastroenterology, 1985;88:1205-1208. cited by applicant Fordtran JS, Walsh JH. Gastric Acid Secretion Rate and Buffer Content of the Stomach after Eating. The Journal of Clinical Investigation, 1973;52:645-657. cited by applicant Freston JW. The Pathophysiological and Pharmacological Basis of Peptic Ulcer Therapy. Toxic Pathology, 1988;16(2):260-266. cited by applicant James RMV. Influence of Intragastric pH on Electrolyte Secretion By the Guinea-Pig Stomach. J. Physiol, 1968;195:623-630. cited by applicant Kolkman JJ, et al. Effect of ranitidine on basal and bicarbonate enhanced intragastric PCO2: a tonometric study. Gut, 1994;35:737-741. cited by applicant Konturek SJ, et al. Effect of acid infusion into various levels of the intestine on gastric and pancreatic secretion in the cat. Gut, 1969;10:749-753. cited by applicant Walsh JH, et al. pH Dependence of Acid Secretion. The Journal of Clinical Investigation, 1975;55:462-468. cited by applicant Cho C H, et al.; Effects of Zinc Chloride on Gastric Secretion and Ulcer Formation in Pylorus-Occluded Rats; European Journal of Pharmacology 1976; 38:337-341. cited by applicant Kuwayama H et al.; study of peptic ulcer in the time of H. pylori. Nippon Rinsho (Japanese Clinics) (extra edition) 2002; 60 (Suppl. 2): 717-720. cited by applicant |
| Primary Examiner: | Soroush, Ali |
| Attorney, Agent or Firm: | Coleman, Henry D. Sudol, R. Neil |
| رقم الانضمام: | edspgr.11510894 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |